X4 Pharmaceuticals Inc (XFOR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, X4 Pharmaceuticals Inc (XFOR) has a cash flow conversion efficiency ratio of -0.116x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.60 Million) by net assets ($168.45 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of X4 Pharmaceuticals Inc to measure how much of total assets are equity-financed.
X4 Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how X4 Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check X4 Pharmaceuticals Inc (XFOR) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
X4 Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of X4 Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Meteoric Resources NL
F:RNF
|
-0.820x |
|
BTS Group AB (publ)
ST:BTS-B
|
-0.001x |
|
Xinjiang Torch Gas Co Ltd
SHG:603080
|
0.075x |
|
Zhongxing Shenyang Commercial Building Group Co Ltd
SHE:000715
|
0.029x |
|
ShenZhen V&T Technologies Co Ltd
SHE:300484
|
-0.010x |
|
Tharisa plc
JSE:THA
|
0.048x |
|
Hangzhou Prevail Optoelectronic Equipment Co Ltd
SHE:300710
|
0.023x |
|
Jiangsu Hualv Biological Technology Co.Ltd.
SHE:300970
|
N/A |
Annual Cash Flow Conversion Efficiency for X4 Pharmaceuticals Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of X4 Pharmaceuticals Inc from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see X4 Pharmaceuticals Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $186.29 Million | $-85.62 Million | -0.460x | +92.22% |
| 2024-12-31 | $22.15 Million | $-130.90 Million | -5.910x | -212.91% |
| 2023-12-31 | $51.10 Million | $-96.51 Million | -1.889x | -81.40% |
| 2022-12-31 | $74.05 Million | $-77.10 Million | -1.041x | +5.41% |
| 2021-12-31 | $64.41 Million | $-70.91 Million | -1.101x | -36.25% |
| 2020-12-31 | $72.80 Million | $-58.82 Million | -0.808x | -117.26% |
| 2019-12-31 | $129.22 Million | $-48.05 Million | -0.372x | +68.40% |
| 2018-12-31 | $21.60 Million | $-25.42 Million | -1.177x | -147.89% |
| 2017-12-31 | $58.71 Million | $-27.87 Million | -0.475x | -136.69% |
| 2016-12-31 | $-16.72 Million | $-21.64 Million | 1.294x | -47.68% |
| 2015-12-31 | $-4.37 Million | $-10.82 Million | 2.473x | -- |
About X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections… Read more